• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alkermes plc - Ordinary Shares (NQ:ALKS)

    44.18 -0.33 (-0.74%)
    Streaming Delayed Price Updated: 3:11 PM EDT, Jun 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 913,295
    Open 45.25
    Bid (Size) 44.15 (500)
    Ask (Size) 44.19 (100)
    Prev. Close 44.51
    Today's Range 43.98 - 45.76
    52wk Range 25.16 - 45.71
    Shares Outstanding 166,121,384
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
    From Alkermes plc
    Via Business Wire

    Performance

    YTD
    +56.3%
    +56.3%
    1 Month
    +18.8%
    +18.8%
    3 Month
    +62.4%
    +62.4%
    6 Month
    +57.6%
    +57.6%
    1 Year
    +48.4%
    +48.4%

    More News

    Read More
    News headline image
    Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears ↗
    Via MarketBeat
    Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss ↗
    Via Chartmill
    Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential ↗
    Via Chartmill
    Alkermes PLC (NASDAQ:ALKS) Reports Strong Q4 Earnings Beat Amid Muted Market Reaction ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes (ALKS) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Alkermes plc Reports First Quarter 2026 Financial Results
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes to Report First Quarter Financial Results on May 5, 2026
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
    From Alkermes plc
    Via Business Wire
    News headline image
    Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
    From Alkermes plc
    Via Business Wire
    News headline image
    Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
    Via MarketMinute
    News headline image
    Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
    From Alkermes plc
    Via Business Wire
    News headline image
    The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
    Via Finterra
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes to Present at the Stifel 2026 Virtual CNS Forum
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes (ALKS) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes plc Announces CEO Succession Plan
    From Alkermes plc
    Via Business Wire
    News headline image
    Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
    From Alkermes plc
    Via Business Wire

    Frequently Asked Questions

    Is Alkermes plc - Ordinary Shares publicly traded?
    Yes, Alkermes plc - Ordinary Shares is publicly traded.
    What exchange does Alkermes plc - Ordinary Shares trade on?
    Alkermes plc - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Alkermes plc - Ordinary Shares?
    The ticker symbol for Alkermes plc - Ordinary Shares is ALKS on the Nasdaq Stock Market
    What is the current price of Alkermes plc - Ordinary Shares?
    The current price of Alkermes plc - Ordinary Shares is 44.18
    When was Alkermes plc - Ordinary Shares last traded?
    The last trade of Alkermes plc - Ordinary Shares was at 06/18/26 03:11 PM ET
    What is the market capitalization of Alkermes plc - Ordinary Shares?
    The market capitalization of Alkermes plc - Ordinary Shares is 7.34B
    How many shares of Alkermes plc - Ordinary Shares are outstanding?
    Alkermes plc - Ordinary Shares has 7B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.